Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/31/2013US20130289010 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
10/31/2013US20130289009 Use of at least one coproduct from the vegetable oil refining industry for obtaining a purified total unsaponifiable vegetable oil product
10/31/2013US20130289008 Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc.
10/31/2013US20130289007 Methods for using 1,2,4-oxadiazole benzoic acid compounds
10/31/2013US20130289006 Compositions for treating hyperpigmentation and methods of use thereof
10/31/2013US20130289005 Acne Vulgaris Treatment Regimen
10/31/2013US20130288999 Compositions and methods for modulation of vascular structure and/or function
10/31/2013US20130288998 Self-Gelling Alginate Systems and Uses Thereof
10/31/2013US20130288997 Nucleoside phosphoramidates
10/31/2013US20130288996 Method for treating and preventing arthritis
10/31/2013US20130288995 Methods for administration of citicoline in stroke treatment
10/31/2013US20130288994 Ready to be infused gemcetabine solution
10/31/2013US20130288989 New use of chemical ingredients in cynomorium as phytoestrogen
10/31/2013US20130288985 Compositions and methods of treatment of corneal endothelium disorders
10/31/2013US20130288984 Combination
10/31/2013US20130288983 Variant activin receptor polypeptides and uses thereof
10/31/2013US20130288981 Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
10/31/2013US20130288977 Method of regulating neuronal axon elongation
10/31/2013US20130288957 Oral combination therapy for treating hcv infection in specific patient subgenotype populations
10/31/2013US20130288956 Combined pharmaceutical composition as antifungal agent
10/31/2013US20130288371 Use of parthenolide derivatives as antileukemic and cytotoxic agents
10/31/2013US20130287871 Refreshing beverage
10/31/2013US20130287867 Composition usable in the treatment of cellular degeneration
10/31/2013US20130287866 Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation
10/31/2013US20130287864 Method for producing bioactive agent, bioactive agent produced thereby, cosmetic, freshness-maintaining agent, growth promotion agent, soil conditioning agent, and pharmaceutical stock solution
10/31/2013US20130287860 Antimicrobial agents and methods of use
10/31/2013US20130287858 Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
10/31/2013US20130287854 Compositions and uses
10/31/2013US20130287851 Liquid ganaxolone formulations and methods for the making and use thereof
10/31/2013US20130287849 Formulations and methods for the controlled release of active drug substances
10/31/2013US20130287848 Bromocriptine Formulations
10/31/2013US20130287847 Solid Molecular Dispersion
10/31/2013US20130287846 Abuse-proofed oral dosage form
10/31/2013US20130287845 Oral Drug Delivery System
10/31/2013US20130287843 Abuse resistant capsules
10/31/2013US20130287834 Anti-adherent formulation including a cationic or nonionic acrylate co-polymer
10/31/2013US20130287823 Patch
10/31/2013US20130287821 Pharmaceutical formulation for reducing frequency of urination and method of use thereof
10/31/2013US20130287819 Bioadhesive polymer-based controlled-release systems, production process and clinical uses thereof
10/31/2013US20130287817 Flowable implant with crosslinkable surface membrane
10/31/2013US20130287797 Combination of cd37 antibodies with bendamustine
10/31/2013US20130287792 Compositions and methods to block mtb-mediated evasion
10/31/2013US20130287791 Modulation of histone h2b monoubiquitination and treatment of cancer
10/31/2013US20130287789 Organic Compounds
10/31/2013US20130287779 Humanized anti-egfl7 antibodies and methods using same
10/31/2013US20130287774 Prevention of Adverse Effects Caused by CD3 Specific Binding Domains
10/31/2013US20130287769 Treatment of solid tumors with rapamycin derivatives
10/31/2013US20130287768 Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
10/31/2013US20130287767 Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
10/31/2013US20130287765 Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
10/31/2013US20130287763 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
10/31/2013US20130287758 Injectable Amino-Acid Composition
10/31/2013US20130287757 Composition for the regeneration of atrophic tissues
10/31/2013US20130287756 Composition and method to alleviate joint pain
10/31/2013US20130287753 Compositions and Methods for Cartilage Repair
10/31/2013US20130287737 Poxviral Oncolytic Vectors
10/31/2013US20130287732 Neuroprotection in Demyelinating Diseases
10/31/2013US20130287731 Hepatitis c virus inhibitors
10/31/2013US20130287730 Piperazine-piperidine compounds as hepatitis c virus inhibitors
10/31/2013US20130287725 Biocompatible polymers, process for their preparation and compositions containing them
10/31/2013US20130287724 Anti-adherent formulation including an anionic or nonionic polymer
10/31/2013US20130287718 Skin external preparation and method of producing same
10/31/2013US20130287712 Foaming formulations including silicone-based polyurethanes
10/31/2013US20130287708 Natural formulations
10/31/2013US20130287705 Method of treating mucosal inflammation
10/31/2013US20130287704 Article and methods for oral self-administration of nicotine
10/31/2013US20130287692 Rifamycin derivatives
10/31/2013US20130287688 Novel compositions and uses of anti-hypertension agents for cancer therapy
10/31/2013US20130284168 Drug Delivery System And Method For Conscious Sedation/Analgesia
10/31/2013DE59209330C5 Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Benzimidazoles, pharmaceutical compositions containing them and methods for their preparation
10/31/2013DE202011110413U1 Zusammensetzung zum Verzögern und Verbessern einer photoinduzierten Netzhautschädigungund von Katarakten unter Verbesserung eines Xerophthalmiesyndroms unter Verwendung vonOmega-Cholin Composition for delaying and improving a photoinduced Netzhautschädigungund of cataracts with improvement of Xerophthalmiesyndroms using vonOmega-choline
10/30/2013EP2657246A1 Modulator of activity of adenylate cyclase
10/30/2013EP2657245A1 Fructosylated mangiferin and preparation method therefor and use thereof
10/30/2013EP2657244A1 Glycoside compound
10/30/2013EP2657242A2 Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof
10/30/2013EP2657241A1 Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient
10/30/2013EP2657238A1 Macrolide compound having anticancer effect
10/30/2013EP2657236A1 Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof
10/30/2013EP2657235A1 Compound containing basic group and use thereof
10/30/2013EP2657234A1 Optically-active diazabicyclooctane derivative and method for manufacturing same
10/30/2013EP2657233A1 3,5-disubstituted alkynylbenzene compound and salt thereof
10/30/2013EP2657231A2 Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
10/30/2013EP2657230A1 Amide derivative and use thereof
10/30/2013EP2657227A1 Novel substituted isoquinoline derivative
10/30/2013EP2657225A2 Substituted methyl amines, serotonin 5-ht6 receptor antagonists, methods for the production and use thereof
10/30/2013EP2657223A1 Metal-salen complex compound and production method for same
10/30/2013EP2657221A1 Preparation of rasagiline and salts thereof
10/30/2013EP2656860A1 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
10/30/2013EP2656857A1 Oral liquid formulation
10/30/2013EP2656856A2 Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release
10/30/2013EP2656855A2 Pharmaceutical preparation for the treatment of depressive pathologies, comprising a protein with a high tryptophan-LNAAs (Large Neutral Amino Acids) ratio
10/30/2013EP2656852A2 "mitseostin" pharmaceutical composition for stimulating the regeneration of supporting tissue and articular cartilage (embodiments)
10/30/2013EP2656851A1 Semuloparin for improving the survival of patients with cancer
10/30/2013EP2656850A2 Oligonucleotides for the treatment or alleviation of edema
10/30/2013EP2656849A1 Liposome comprising combination of chloroquine and adriamycin and preparation method thereof
10/30/2013EP2656848A1 Ready to be infused gemcitabine solution
10/30/2013EP2656847A2 Conjugate for photodynamic diagnosis or therapy and method for preparing same
10/30/2013EP2656846A1 Phosphomycin pharmaceutical composition
10/30/2013EP2656845A1 Composition for modulating stem cell growth with prostaglandins
10/30/2013EP2656844A1 Antineoplastic combinations containing HKI-272 and vinorelbine
1 ... 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 ... 7860